Anti cell proliferative
- Pericyte Protective Agent
- Long-acting CGRP
- Long-acting Pramlintide
- Anti cell proliferative
LCT 0.047 Last updated EOD 18th January 2019
The following fact sheets provide a summary of our current business and research pipeline.
Anti Cell Proliferative
Gliomas are the most common primary brain tumour, making up 81 percent of malignant brain tumours. Although relatively rare, they are highly malignant. Glioblastoma, the most common glioma, has a 5-year relative survival of less than 5 percent. There is currently no cure.
Working with Sir Richard Faull’s Centre for Brain Research, we are evaluating compounds that prevent human glioma cells from proliferating in vitro. The next step is to confirm the lead compound and test in an animal model of glioma.
If successful, that compound would be further developed to undertake the first clinical trial in patients. The investigator would be neurosurgeon Mr Patrick Schweder at Auckland Hospital.